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There is an increasing awareness that health care must move from post-symptomatic
treatment to presymptomatic intervention. An ideal system would allow regular inexpensive
monitoring of health status using circulating antibodies to report on health fluctuations.
Recently, we demonstrated that peptide microarrays can do this through antibody signatures
(immunosignatures). Unfortunately, printed microarrays are not scalable. Here we
demonstrate a platform based on fabricating microarrays (B10M peptides per slide,
330,000 peptides per assay) on silicon wafers using equipment common to semiconductor
manufacturing. The potential of these microarrays for comprehensive health monitoring is
verified through the simultaneous detection and classification of six different infectious
diseases and six different cancers. Besides diagnostics, these high-density peptide chips have
numerous other applications both in health care and elsewhere.
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E
arly, presymptomatic detection and treatment of disease
often affords a much higher probability of favourable
outcome than does intervention at later stages, common
with symptomatic presentation (for example, ref. 1). This is
particularly the case with many chronic diseases such as cancer,
where resection at stage 1 often results in an effective cure that is
nearly impossible to achieve once metastasis has taken place. In
addition, early detection is expected to lower health-care costs2.
However, moving from a reactive, symptom-based treatment of
disease to a proactive, data-based health-maintenance paradigm
will almost certainly require the development of very low cost,
comprehensive molecular diagnostic tools that are simple to
implement and minimally invasive. Current biomarker research
has focused on the development of single molecular biomarkers3
or small panels of biomarkers4, and essentially always for one or a
small family of diseases. Thus far, this kind of biomarker research
has yielded relatively few validated markers, even though a great
deal of effort and resources have been expended in their
development5–7.
We recently demonstrated the feasibility of a fundamentally
different approach to diagnosis, purposefully aligned with the
concept of proactive health monitoring. This approach involves
measuring the profile of the circulating antibodies, referred to as
an immunosignature. The assay itself requires o1 ml of blood,
and the blood can be sent via mail as a drop dried on a piece of
filter paper8. The blood is diluted with little or no additional
processing and incubated with a large array of different non-
natural-sequence peptides (reviewed in Sykes et al.9). Our initial
platform was an array of 10,000 presynthesized peptides spotted
on a glass slide, and we have used this format to characterize
immune responses to vaccines10, infectious diseases11,
cancer12,13, Alzheimer’s Disease14 and autoimmune disorders12.
The work on brain cancer13 was performed as a blinded train/test
study, training on a patient cohort taken in 2007 and testing on a
cohort from 2010, with 100% accuracy of identification. We have
also shown that it is feasible to detect signatures before the onset
of symptoms in mouse models15 and in human pre-pancreatic
cancer samples12. Importantly, because the peptide sequences are
not from any particular proteome, but from non-natural-
sequence space, all of the immunosignature diagnoses published
and in review to date were carried out with essentially the same
array of 10,000 peptides. The biochemical and biophysical
features required to create immunosignatures have been studied
in detail16.
The work cited above has been performed using peptides
spotted on glass slides. Such arrays are inherently limited by the
density of peptides that can be physically spotted, the scalability
and reproducibility of fabrication, and ultimately the cost per
assay. Many issues arise because of the heterogenic nature of
presynthesized peptide chemistry. Ensuring solubility, exact
concentration and purity of thousands of peptides stored in
liquid buffer is remarkably challenging and affects the ultimate
quality of the microarray. The large number of circulating
antibodies (B109)17 suggest that arrays with more peptides than
the current 104 would offer better resolution of disease signatures.
The most advanced form of spotted arrays has been reported by
Frank18 using the SPOT technology. Peptides are synthesized on
spots on filters, the spots individually removed, the peptides
released and spotted on glass slides. Densities of 40 features per
slide have been obtained19. Although the production and utility of
low to moderate sized peptide arrays has been demonstrated20,21,
much higher feature densities and more consistent peptide quality
should be attainable by using in situ peptide synthesis. In situ
synthesis of peptides was first demonstrated more than 20 years
ago22; however, to date, the peptide arrays that are commercially
available or reported in the literature would not be able to achieve
the requirements of low cost, high volume, with well-
characterized composition and diagnostic effectiveness that
would be needed for a broadly used early diagnostic platform.
Recently Price et al.23 demonstrated the use of photolithography
to synthesize peptide arrays on silicon wafers, creating arrays of
9,096 peptides using eight different amino acids. Although that
study did not demonstrate scalability, number or complexity of
peptides needed for health monitoring using immunosignatures,
it and other reports18,22,24–26 have shown the potential for
peptide array production using the highly refined equipment and
techniques of the electronics industry. Using a maskless, light-
directed system, Nimblegen-Roche has produced arrays of high
density (potentially 2M per slide) but this system is low volume
production. PEPperPRINT Inc. (Heidelberg, Germany) produces
peptide arrays using a process based on electrostatic deposition
and conjugation of dry amino acids, similar to the method used
by laser printers. These arrays are also low volume production
and, although they can produce up to 775 peptides per cm2, the
arrays are tuned more for epitope detection than
immunosignaturing27. A problem yet to be solved with all
in situ systems reported to date is the molecular characterization
of the peptides. Most reports qualify the arrays using detection of
a few linear epitopes that bind well-characterized, commercially
available monoclonal antibodies. However, this says little about
chemical purity of the sequences. The lack of direct, in situ
chemical analysis remains a major roadblock in the development
of high-quality peptide arrays.
Here we demonstrate the production of high-density peptide
arrays on silicon wafers using scalable manufacturing approaches
that lend themselves to low cost and high volume. These arrays
have the number of features, quality of peptides and the amino-
acid complexity required for immunosignatures. The chemical
identity and purity of the in situ synthesis on these arrays is
characterized directly by imaging mass spectrometry, using
methods we previously developed28. Finally, we demonstrate
that immunosignatures generated using these arrays can
discriminate multiple different infections and cancers from each
other with statistical confidence that is as good or better than the
printed arrays that have been the basis of our previous work.
Results
Quality control of peptide synthesis. Specificity of the nine
monoclonal antibodies (HA, Ab1, Ab8, Cdc2, DM1A, LNKB2,
HSV, 4C1 and A10) to their cognate sequence is high, even in the
presence of 4330,000 other random-sequence peptides (Fig. 1a,
left panel). Interestingly, each monoclonal antibody tested
demonstrates unique behaviour relative to non-cognate peptide
sequences16. For TP53 Ab1 (AbCam, Preston, MA, USA), for
example, there are 209 perfect match epitope sequences (RHSVV)
and 98 single-residue mismatch peptides (RHSVG) scattered
across each array. We measured the 209 perfect match peptides
relative to binding of TP53 Ab1 and obtained a coefficient of
variation o5%. We measured a 26-fold difference in average
intensity between these 209 perfect match peptides and the 98
single mismatch peptides. As we have previously published, a
given monoclonal antibody may exhibit high binding to
sequences that are quite divergent from the known epitope16.
While reaction with monoclonal antibodies is the current
standard for quality assessment of peptides synthesized in
commercial arrays (as shown in Fig. 1a), this type of analysis
does not provide information about the chemical purity or
composition of the peptides in each feature, nor does it allow
evaluation of the efficiency of individual steps in the process. The
chemical purity and yield of synthesis of peptides on the arrays
manufactured by HealthTell Inc. (Chandler, AZ, USA) for this
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study was analysed by generating 200-mm test features on the
same wafers as the immunosignature arrays and performing
MALDI (matrix-assisted laser desorption ionization) mass
spectrometry imaging on those features, after gas phase release
of peptides from the surface (Fig. 1b, left panel). Mass spectra of
three of these features, each a variant of the epitope for the
monoclonal antibody DM1A, are shown, demonstrating that the
appropriate sequences were generated. A fluorescent image of the
same array features is also shown (Fig. 1b, right panel),
demonstrating specific binding of the antibody to the cognate
sequence (AALEKDY). Figure 1c shows mass spectra of several
peptides made with 23 coupling steps, showing that long
sequences can effectively be generated. Figure 1d shows a series
of spectra from shorter peptides that differed from each other in
only three amino acids. Coupling yields of the three variable
amino acids were estimated by comparing the ion intensity of the
full-length peak with the ion intensity observed at the positions
expected for each possible amino-acid deletion (see arrows). The
yields shown in Fig. 1e for each amino acid represent the average
of results from multiple peptides containing that amino acid. The
average yields are at or above those achieved by bead-based
peptide synthesis. We were unable to estimate yields for histidine
and tryptophan as peptides containing these amino acids appear
to be partially oxidized during analysis. However, the monoclonal
antibody results from Fig. 1a suggest that both of the amino acids
are incorporated, as those epitopes contain both W and H. We
conclude that the designated peptides are synthesized in high
yield.
Immunosignature diagnostic performance. The other question
in qualifying the system is whether these arrays can reproducibly
generate immunosignatures from patients with the same disease.
Figure 2 demonstrates this capability. The top left portion of
Fig. 2 demonstrates the simultaneous discrimination between six
different cancer cohorts (breast cancer, Glioblastoma multiforme,
multiple myeloma, oesophageal cancer, ovarian cancer and lung
cancer) and healthy normal controls each using sera from 10
different patients. Figure 2 top right demonstrates the
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Figure 1 | Fidelity and stepwise yield of in situ peptide synthesis. (a) Cognate epitopes for monoclonal antibodies p53Ab8 (epitope: SDLWKL), p53Ab1
(RHSVV) and DM1A (AALEKD) were synthesized 2,163 times as part of the 330,000 feature array. Average binding levels of each monoclonal antibody
(Ab probe) with each epitope (nine measurements) are shown and normalized to binding to the cognate epitope. (b) The DM1A epitope and several
variants were synthesized in 200-mm features on the same wafer. Both a MALDI image (different colours represent different molecular weights) and a
fluorescence image of labelled DM1A Ab binding are shown. MALDI spectra extracted from several of the imaged features over a 160D mass range are
provided. The small peak to the right of the main peak represents incomplete side chain deprotection. (c) MALDI mass spectra from individual 200-mm
features in which peptides containing 21 amino acids plus a tris (2,4,6-trimethoxyphenyl)phosphonium-acetyl (TMPP-Ac) group and a 30-atom
polyethylene glycol linker were synthesized. (d) A series of 10-mer peptides were synthesized in 200-mm features that differed only in three amino acids
(bold and underlined). The full-length peptide and the expected mass for each of the single deletion products of the variable amino acids are shown
(marked by arrows). (e) The yields for each amino acid determined from measurements described in part (d). Measurements of multiple peptides
containing each amino acid gave s.e.’s of 1% or less. The conditions used to release the peptides from the surface appear to affect the MALDI signals for Trp
and His, so yields for these amino acids are not known.
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discrimination between six different infectious disease cohorts
(Dengue fever, Valley fever, Lyme disease, West Nile Virus,
Bordetella pertussis (whooping cough) and Treponema palladium
(Syphilis) and healthy normal controls, each using sera from 10
different patients (with the exception of B. pertussis with five
patients). The peptide intensities for each individual were
screened statistically to find the peptides that best represent
common reactivity within a disease cohort, with simultaneously
low signal in other diseases (GeneSpring 7.3.1, Agilent, Santa
Clara, CA, USA). Each peptide feature was selected for both high
sensitivity (to detect low copy antibodies) and high specificity
(selected peptides should respond to only one disease). A total of
350 peptides (50 per cohort) were selected for the cancer samples
(Fig. 2, top left) and for the infectious disease samples (Fig. 2, top
right). More than 50 peptides met the requirements for each
condition; however, only the top 50 were used in this analysis.
Previous studies indicated information content should peak
between 20 and 100 features per disease16 and the performance of
linear classifiers tends to suffer as the total number of features
increases29. The top 50 informative peptides and important
sequence motifs are listed in Supplementary Tables 1 and 2. As
described below (see Analysis), the peptide features that showed
common reactivity to each cohort were highly significant
statistically. To date, no diagnostic of which we are aware can
simultaneously discriminate between six cancers and six
infectious diseases using the same platform.
Statistical analysis of immunosignature performance. The
immunosignature data in Fig. 2 were analysed using Type I
analysis of variance (ANOVA) analysis followed by feature
selection using pattern matching to restrict peptides to those with
the highest contrast between each disease and all other samples.
The 350 peptides shown in Fig. 2 top left (six cancers and normal
controls) had ANOVA P values less than or equal to 10 21. A
1,000 permuted t-test (labels between oesophageal cancer and
healthy controls were shuffled 1,000 times) gives no
P values less than 10 4, suggesting that patterns do not arise
randomly but are specific to each disease cohort. For comparison,
a similar experiment of five different cancer cohorts, 20 persons
each, using a printed peptide array of 10,000 random-sequence
peptides yielded 100 peptides with Po10 14 or smaller by
ANOVA. The 350 peptide feature intensities displayed in Fig. 2
top right arose from an analysis of six different infectious diseases
versus healthy controls. ANOVA yielded 350 peptides with
Po10 22 or smaller. A 1,000 permuted t-test gave P values
410 4. A similar analysis of 45 Valley Fever patients versus 34
controls gave 243 peptides with Po10 17.
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Figure 2 | Immunosignature performance. Heatmaps (top left and right) indicate groupwise specificity of peptide signals with hierarchical clustering
performed on 350 peptides (y axis) and 60 patients plus 10 controls (x axis) with Euclidean distance used as the measure of separation. The order of each
patient and peptide is calculated from the distance measure using hierarchical clustering. Classification of all samples was 100% accurate using either
linear discriminant analysis or support vector machine (SVM) with leave-one-out cross-validation. Top left: serum from six different cancers with 10
patients in each group (BC, breast cancer, GBM, Glioblastoma multiformae, MM, multiple myeloma, EC, oesophageal cancer, OV, ovarian cancer, LNG, lung
cancer) was analysed using the 330,000 peptide microarray. The striking stair-step pattern is because of the clustering algorithm alone. Top right: Sera
from six different infectious diseases, with 10 patients in each group except BP, with five patients (Dengue, dengue virus, VF, Coccidioides immitis, BP, B.
pertussis, Lyme, Borrelia burgdorferi, WNV, West Nile Virus, TP, T. pallidum and healthy donors (ND) were likewise analysed. Each sample set achieved 100%
accuracy using SVM as the classifier and leave-one-out cross-validation. Below left: a plot of log10 P value (x axis) versus log2 fold-change (y axis) between
10 randomly selected patients at the time of diagnosis with oesophageal cancer (numerator) and 10 otherwise healthy controls (denominator) displays the
distribution of significant peptides and the resulting ratios. In all, 562 peptides with P-valo3 10 7 are coloured red, yielding a 0.017% false-positive rate.
Lower right is a power plot demonstrating the minimum detectable fold-change (delta, black line, calculated using the command power.t.test() in R) along
the x axis. This power plot is reviewed in detail in ref. 30. The blue bars (y axis) represent every peptide’s average log2 ratio between 10 oesophageal cancer
patients (numerator) and 10 healthy controls (denominator). The red circles indicate the same peptides as in the graph to the left (Po3 10 7).
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Figure 2 bottom left demonstrates the relationship between
array-to-array precision and the associated ability to detect
changes between patients with oesophageal cancer and healthy
controls. The log2 ratio across the cohort of eight oesophageal
cancer patients versus eight healthy volunteers is plotted on the y
axis. Peptides that have higher intensity for the oesophageal
cancer patients than controls are plotted above the x axis (positive
log2 ratio), those that are lower in oesophageal patients than
controls are below the x axis. The log10 P value is plotted along
the x axis. The red circles indicate those peptides that are
significant at Po1 10 6. Figure 2 lower right is a power plot of
the same data. The log2 ratio is plotted as blue bars extending
above the x axis (peptides higher in oesophageal cancer than
control) or below the x axis (peptides lower in oesophageal cancer
than control). The black curve indicates the minimal detectable
fold-change for each of the 330,000 peptides calculated by an a
posteriori power analysis that was calculated using a two-sided
power test with alpha¼ 0.05, beta¼ 0.20, N¼ 10 per arm, actual
s.d. calculated per peptide. The closer the black line is to the x
axis, the more precision that peptide has, and the smaller the
difference that peptide was able to detect. Peptides on the far right
of the power chart indicate those peptides where precision is low
and the minimum detectable fold-change is very high. Red circles
are the same significant peptides (Po1 10 6) as in the volcano
plot on the left. The power plot and volcano plot represent the
general performance of the 330,000 peptide microarray, which far
exceeds the precision inherent in modern commercial expression
microarrays30. There are 23,323 informative peptides on the array
that contribute to distinguish oesophageal cancer patients from
healthy controls. We do not imply that the particular peptide
signatures for each condition constitute a diagnostic for that
disease; that would require larger cohorts and blinded tests.
However, these results indicate that the high-density arrays can
produce consistent immunosignatures, an important step in
enabling large-scale applications of immunosignaturing.
Discussion
Past work has demonstrated the potential of immunosignature
technology as a useful diagnostic for detection of chronic disease
and infectious disease, symptomatic12,13,16 as well as early15.
However, the research platform upon which most of this work
was based is difficult to produce at volume and low cost and
limited in the number and density of peptide features. Here we
demonstrate the production, chemical characterization and
diagnostic potential of high-density peptide microarrays on a
manufacturing platform that can easily be scaled and follows the
same kind of cost/volume characteristics and electronics
manufacturing. We believe the greatest potential impact of
these arrays is enabling regular, comprehensive health
monitoring. The number of unique peptides in these arrays
makes it feasible to detect and distinguish many different
disease signatures simultaneously. The scalability and associated
low cost of the process should make it feasible for individuals
to monitor their health on a frequent basis, providing the
additional advantage of establishing a robust personal health
baseline.
Using arrays of non-natural peptide sequences designed to
evenly represent combinatorial sequence space has the advantage
of making the immunosignature platform a universal diagnostic
technology. For any new condition, a new format or physical
array is not needed; the same data simply need to be analysed in
terms of a different reference signature. However, a disadvantage
of this approach relative to using peptide sequences from known
proteomes is that the signatures cannot be directly ‘read’ back to
the original antigen. The identity of the antigen would have to be
inferred informatically from the collection of peptides that makes
up a signature (see Supplementary Tables 1 and 2). The larger
number of peptides available in the 330,000 peptide arrays
facilitates this process.
Obviously, high density, low cost, peptide arrays have many
other possible uses besides health monitoring. Peptide arrays have
been used to assay kinase activity and inhibitors23,31, map
monoclonal antibodies32, identify autoantigens33, even bind
proteins34 and cells35. The synthesis fidelity and peptide density
of these arrays make it feasible to tile the entire human proteome
or the proteomes of most human pathogens for studies of
autoimmunity or vaccine development23,26,36. Random-sequence
arrays have been the starting point for developing synthetic
antibodies34,35,37,38 using branched peptides, and a screening
system for identifying antimicrobial peptides35. We expect this
platform will find many other uses.
Methods
Lithography-based peptide array synthesis. The procedure for synthesis of the
arrays is shown schematically in Fig. 3a. The arrays were fabricated to specification
by HealthTell Inc. for the studies described here. A 520-nm thermal oxide-coated
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Figure 3 | Immunosignature array synthesis. (a) Mask-based patterned synthesis of peptides was performed on 200-mm silicon wafers with thermal
oxide coating, starting with an aminosilane–glycine monolayer and building peptides through cycles of patterned acid formation in a photoresist
removing Boc groups from the N-terminal amines of nascent peptides and coupling of the next amino acid. (b) The wafer is diced into microscope slide-
sized regions (75 25mm), each of which contains 24 arrays of 300 and 30,000, 8-mm features. Samples can individually be applied to each array
via a commercially available gasket system and scanned on a laser scanner. On the far right is an image of the array (at  800 magnification) of serum
applied to the array and detected with fluorescent secondary antibody.
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silicon wafer surface is derivatized with a monolayer of aminosilane to create
peptide attachment sites, and Boc-glycine is uniformly attached to the surface.
A photoresist containing a photoacid generator is spun on the wafer and exposed
through a defined mask (Topan, Santa Clara, CA, USA) to 365-nm light, resulting
in the patterned deprotection of Boc-protected amines in specific features on the
array. A coupling solution containing a Boc-protected amino acid is then spun on
the wafer and coupling takes place only at the deprotected features. The process is
repeated to create the desired peptide sequence at each feature. For the arrays
described below, a distribution of peptide lengths was intentionally generated
averaging 12 amino acids along with individual peptides ranging from 8 to 17 aa.
This length distribution was chosen because it is similar to the length distribution
of antibody epitopes that range from 5 to 15 aa39. The sequence of each peptide
was pseudo-randomly generated using an algorithm that minimizes the number of
synthetic cycles required, and uses 16 of the 20 natural amino acids, with cysteine,
methionine, isoleucine and threonine excluded. As an immunosignature is not
based on natural sequence space per se, but instead on a representative and diverse
chemical space, it was not necessary to use all amino acids, a fact that simplifies
synthesis, reducing the total number of steps to 90 lithography cycles at B20min
per cycle. Peptide arrays are synthesized with 8-mm features and a 12-mm centre-
to-centre spacing in an orange-crate pattern. The 200-mm wafers are diced into 13
75 25mm slides, each with 24 identical arrays of 330,000 distinct peptides
(B8M peptides per slide) The total assay area of each array is 0.49 cm2 and the 24
assay per slide format allows existing robotics designed for microscope slides and
96-well enzyme-linked immunosorbent assay (ELISA) plates to be used with no
modification. Scanning of the slides is performed using commercially available
laser scanners. If configured as a single array, the system could produce B10M
different peptides per standard slide.
Assay and scanning. The 24 assay per slide arrangement enables ELISA-based
fluidics systems to be used. Ninety-six-well gaskets and frames were purchased
from ArrayIt (Sunnyvale, CA, USA) that enable four slides to be arrayed in a
96-assay format. A Beckman Biomek FX robot with 96 channel head was used to
transfer solutions to the individual arrays while an integrated Biotek 405TS plate
washer (Biotek, Winooski, VT, USA) was used to wash the arrays between
incubation steps. Assay conditions are described in ref. 16. Briefly, arrays are
deprotected to remove Boc protecting groups40 and blocked in blocking buffer16.
There was no preprocessing of serum; 1 ml of serum was diluted 5000-fold in
sample buffer16 and 200ml was then applied to each 330,000 peptide subarray,
incubated for 1hr at 23 C, washed, and then labelled with a fluorescent secondary
antibody for human IgG16. The BioTek ELx405 plate washer is programmed to
wash four separate 24-up arrays four times for five minutes each using incubation
buffer. Note that the microarrays are designed to fit into standard laser scanners.
The fluorescent intensity at each peptide was measured using an Innoscan 900
1 mm scanner (Innopsys, Chicago, IL, USA) using the 545-nm laser, scanned at
1 mm resolution. Each subarray was scanned and aligned separately, with 24 high-
resolution Tagged Image File Format images produced per slide.
Quality control. The accuracy of the immunosignaturing platform relies on the
production of highly reproducible arrays of peptides that are both chemically
consistent from array to array and are accessible for antibody binding. Immuno-
signature and other applications depend on the chemical fidelity of peptide
synthesis as well as the density of peptides at each feature. A quantitative analysis of
the chemical composition of peptide features on immunosignature arrays is given
in Fig. 1 using high-resolution mass spectrometry performed by NextVal Inc. (San
Diego, CA, USA). In Fig. 1a, multiple copies of three different epitope sequences
were synthesized in a randomly distributed manner and probed with the appro-
priate monoclonal antibodies. Each monoclonal bound its own epitope on the array
at least 100-fold higher than either of the other two. The current masks enable
thousands of versions of the linear epitopes for each of nine different commercially
available monoclonal antibodies HA [HA tag, sequence: YPYDVPDYA, Rockland
Antibodies, Rockland, MD], Ab1 [Hu TP53, sequence TFRHSVVV, aa210–218,
Clonetech, Palo Alto, CA], Ab8 [Hu TP53, sequence TFSDLWKLLPE, aa18–28,
LabVision/Thermo, Anthem AZ], Cdc2 [Hu Cyclin Dependent Kinase 1, sequence:
TPNNEVWPEVE, aa 221–231, Abcam, Cambridge, UK], LNKB2 [Hu Inter-
leukin2,sequence: KPLEEVLNL, aa64-72, Santa Cruz Biotech, Dallas TX], DM1A
[Hu Tubulin alpha subunit, sequence: AALEKDYEEVGV, aa 73–85, Life Tech-
nologies, Carlsbad, CA], HSV [HSV1, sequence: QPELAPEDPED, aa379–389,
Abcam, Cambridge, UK], 4C1 [hTSHr Hu Insulin receptor, sequence: QAFDSHY,
aa379–385, Santa Cruz Biotech], A10 [hTSHr Hu Insulin receptor, sequence:
EEDFRVT, aa33–40, Santa Cruz Biotech] to appear at scattered locations
across each array. The epitopes appear as written or with random surrounding
sequence.
Human subjects. Human serum was used to test the microarrays for the ability to
produce accurate and reproducible immunosignatures, as in refs 13,16.
Retrospective collections of serum or plasma work as well as newly drawn
samples8. The infectious disease samples were purchased from SeraCare Life
Sciences (Milford, MA, USA) and were consented upon collection. Cancer samples
were acquired from collaborators and were consented upon collection through the
institute’s own IRB. All samples were anonymized before receipt at ASU via
Institutional Review Board (IRB) no. 0912004625, ‘Profiling Biological Sera for
Unique Antibody Signatures’ (approved by the Western Institutional Review
Board, Olympia, WA, USA). Healthy volunteers were recruited at Arizona State
University through the aforementioned IRB.
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